GAD65-95tr (Human Glutamic Acid Decarboxylase 65kDa Isoform, 1-95aa truncated)
GAD65 is primarily expressed in neuron cells and pancreas β-cells. It works as a catalyser in GABA synthesis.
Glutamic acid decarboxylase autoantibodies (GADA) are found in 70% to 80% of individuals with new-onset type 1 diabetes, making it the most frequent autoantibody in autoimmune diabetes. GADA can be detected in serum for many years post diagnosis, and high concentrations of GADA have been considered as a marker of faster β-cell exhaustion in these patients. Furthermore, GADA in non-diabetic individuals predicts the later development of type 1 diabetes1. Besides autoimmune diabetes, GADA also exists in Stiff Man Syndrome, autoimmune poly-endocrinopathies, and some of Grave’s Disease patients.
Expressed in Baculovirus-sf9 vector expression system with a total of 515 amino acids (AA).
Mw: 58.8KDa (calculated).
N-terminal 6xHis-tag and TEV cleavage site, 25 extra AA (highlighted).
Recombinant antigen for research use or manufacturing only.
AMINO ACID SEQUENCE
Store at –80°C. Avoid repeated freezing/thawing cycles.
QUALITY CONTROL TEST
BCA to determine quantity of the protein.
SDS PAGE to determine purity of the protein.
Liquid in Phosphate buffer containing NaCl (1M), Na2HPO4 (10mM), KCl (2.7mM) and KH2PO4 (2.0mM) with protease inhibitor, pH8.0.
Standard ELISA test, line/dot assay and microarray assay with positive/negative sera panels.
As an autoantigen, GAD65 binds with IgG-type human autoantibodies.